Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2015-01-21 Share Issue/Capital Cha…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
Flagging PCIB T
Share Issue/Capital Change Classification · 99% confidence The document text is very short (709 characters) and describes a transaction where Photocure ASA sold 1,343,905 warrants ('tegningsretter') in PCI Biotech Holding ASA. It details the resulting shareholding percentage (10.07%) after a forthcoming rights issue. This transaction involves the disposal of rights/shares by an existing shareholder, which strongly suggests insider trading or director/major shareholder dealing, or a transaction in own shares if Photocure was buying back. Since the text explicitly details the sale of rights/shares by an existing major shareholder (Photocure ASA), it fits best under Director's Dealing (DIRS) if Photocure is considered an insider/director, or potentially Transaction in Own Shares (POS) if the context implies a specific corporate action related to capital structure management, although DIRS is often used for significant shareholder transactions by related parties. Given the context of reporting share/warrant transactions by a significant entity, DIRS (Director's Dealing) or MRQ (Major Shareholding Notification) are possibilities. However, the focus is on the *transaction* itself (selling rights), not just the resulting holding percentage crossing a threshold. Since the text details a specific transaction by a major shareholder, and DIRS covers personal share transactions by executives/directors (which often includes related entities reporting transactions), I will classify it as DIRS. If it were purely about the resulting holding percentage, MRQ would be better. Since it details the sale of rights, DIRS is the most appropriate fit among the specific options for reporting share movements by insiders/major holders.
2015-01-21 Norwegian
PCI Biotech: Successful Investigational New Drug application (IND) review for Amphinex
Regulatory Filings Classification · 100% confidence The document is a short announcement from PCI Biotech dated January 20, 2015, regarding receiving clearance from the US FDA for its Amphinex Phase II clinical program in the USA. It details a specific operational/regulatory milestone (IND review clearance) and includes contact information and a boilerplate disclosure statement referencing Norwegian securities law. This type of specific, non-periodic operational update that doesn't fit the standard financial report categories (10-K, IR, ER) is best classified as a general Regulatory Filing (RNS), as it is a mandatory disclosure of a significant event to the market, often falling under general disclosure rules rather than specific financial reporting forms. It is too specific for 'CAP' (financing) or 'LTR' (legal proceedings). Given its nature as a market-sensitive announcement that isn't a standard financial report or management change, RNS is the most appropriate fallback.
2015-01-20 English
Oslo Børs - The subscription rights in PCI Biotech Holding ASA the quoted company will be listed 20.01.2015
Share Issue/Capital Change Classification · 99% confidence The document text is very short (675 characters) and announces the listing details for subscription rights related to PCI Biotech Holding ASA. It specifies dates, ISIN, issue price, and subscription/listing periods. This is a specific announcement regarding a capital structure event (issuance of rights/shares) rather than a full financial report or a general regulatory filing. It most closely aligns with 'Capital/Financing Update' (CAP) as it details the terms of a rights issue, which is a financing activity. It is not a general regulatory announcement (RNS) because it is highly specific to capital structure changes.
2015-01-20 English
Oslo Børs - Tegningsrettene i PCI Biotech Holding ASA vil bli notert fra og med 20.01.2015
Share Issue/Capital Change Classification · 98% confidence The document text is very short (619 characters) and announces the listing/trading details for subscription rights ('Tegningsrettene') related to an issuance ('emisjonen') in PCI Biotech Holding ASA, effective 20.01.2015. It details the ticker, ISIN, subscription price, subscription period, and allocation ratios. This clearly relates to a change in the company's capital structure involving new shares/rights, which aligns best with the 'Share Issue/Capital Change' category.
2015-01-20 Norwegian
PCI Biotech: Prospectus approval and commencement of subscription period
Share Issue/Capital Change Classification · 99% confidence The document explicitly discusses a 'Prospectus approval and commencement of subscription period' for a 'rights issue of 7,000,000 new shares'. It details the subscription price, subscription period, underwriting, and eligibility criteria for shareholders. This content is directly related to a company raising capital through the issuance of new shares to existing shareholders, which falls under the definition of Capital/Financing Update (CAP). Although a prospectus is mentioned, the document itself is an announcement detailing the terms and commencement of the financing activity, not just a generic announcement of a report's publication (RPA) or a general regulatory filing (RNS).
2015-01-20 English
Oslo Børs - The subscription rights in PCI Biotech Holding ASA the quoted company will be listed 20.01.2015
Share Issue/Capital Change Classification · 99% confidence The document text is very short (675 characters) and announces the listing details for subscription rights related to PCI Biotech Holding ASA. It specifies dates, ISIN, issue price, and subscription/listing periods. This is a specific announcement regarding a capital structure event (issuance of rights/shares) rather than a full financial report or a general regulatory filing. It most closely aligns with 'Capital/Financing Update' (CAP) as it details the terms of a rights issue, which is a financing activity. It is not a general regulatory announcement (RNS) because it is highly specific to capital structure changes.
2015-01-19 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.